India, April 7 -- Nektar Therapeutics (NKTR) entered a quiet period beginning this month as it awaits the trial results for its lead drug candidate, Rezpegaldesleukin, in alopecia areata.
Rezpegaldesleukin, also known as Rezpeg, NKTR-358, or formerly LY3471851, is a pegylated recombinant human interleukin-2 (IL-2) therapeutic. This engineered biologic is a modified form of a naturally occurring protein that plays a key role in regulating immune system activity.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....